Inaxaplin Reduces Proteinuria in FSGS With APOL1 Variants
Study findings suggest targeted inhibition of APOL1 function can reduce proteinuria.
Study findings suggest targeted inhibition of APOL1 function can reduce proteinuria.
Obesity rates in glomerular disease have multiplied more than 10-fold over the last 40 years.
The management recommendations for lupus nephritis are poised to change significantly in the coming months, a KDIGO committee revealed.
Among the study findings, primary nephrotic syndrome was associated with an excess risk of heart failure hospitalization.
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Investigators report encouraging results from a small observational study testing the effect of preemptive therapeutic plasma exchange and rituximab in kidney transplant recipients whose primary cause of kidney failure was focal segmental glomerulosclerosis.
Each 1-unit reduction in log-transformed urinary protein-creatinine ratio in patients with focal segmental glomerulosclerosis is associated with a 77% decreased risk of end-stage kidney disease, a study found.
Researchers may have found a predictor for focal segmental glomerulosclerosis (FSGS) in kidney transplant recipients.
Distinguishing primary from secondary focal segmental glomerulosclerosis is crucial because the treatment approaches and therapeutic goals differ.
In a small study, abatacept induced partial or complete remission of focal segmental glomerulosclerosis.